ANGELI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 51.960
AS - Asia 31.462
EU - Europa 14.540
AF - Africa 5.328
SA - Sud America 5.116
Continente sconosciuto - Info sul continente non disponibili 717
OC - Oceania 505
Totale 109.628
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.973
SG - Singapore 9.799
VN - Vietnam 5.131
CN - Cina 4.932
HK - Hong Kong 3.335
BR - Brasile 3.062
IT - Italia 2.813
FR - Francia 1.362
FI - Finlandia 1.338
DE - Germania 1.218
BD - Bangladesh 1.027
PL - Polonia 984
IN - India 957
SE - Svezia 686
GB - Regno Unito 591
RU - Federazione Russa 576
IQ - Iraq 523
TR - Turchia 507
UA - Ucraina 460
AR - Argentina 453
NL - Olanda 395
CA - Canada 370
ES - Italia 369
JP - Giappone 330
ID - Indonesia 327
PH - Filippine 326
PK - Pakistan 325
SA - Arabia Saudita 317
MX - Messico 316
ZA - Sudafrica 259
EC - Ecuador 257
UZ - Uzbekistan 240
CO - Colombia 234
IE - Irlanda 224
VE - Venezuela 211
MA - Marocco 199
AT - Austria 198
KE - Kenya 189
JM - Giamaica 187
AO - Angola 183
EG - Egitto 183
CL - Cile 182
JO - Giordania 181
TN - Tunisia 176
AE - Emirati Arabi Uniti 175
CR - Costa Rica 175
KR - Corea 175
GR - Grecia 172
PY - Paraguay 171
CI - Costa d'Avorio 168
PA - Panama 167
AL - Albania 166
MY - Malesia 164
CZ - Repubblica Ceca 162
ET - Etiopia 160
PE - Perù 159
BJ - Benin 158
LB - Libano 158
TH - Thailandia 154
HN - Honduras 153
DZ - Algeria 151
RS - Serbia 149
NP - Nepal 146
SN - Senegal 146
KG - Kirghizistan 144
PS - Palestinian Territory 144
IL - Israele 143
RO - Romania 143
AZ - Azerbaigian 141
EE - Estonia 141
DO - Repubblica Dominicana 139
TW - Taiwan 139
BA - Bosnia-Erzegovina 138
BF - Burkina Faso 136
BO - Bolivia 136
BY - Bielorussia 136
SK - Slovacchia (Repubblica Slovacca) 136
CH - Svizzera 135
MD - Moldavia 135
KZ - Kazakistan 134
NI - Nicaragua 134
CV - Capo Verde 133
SI - Slovenia 132
DK - Danimarca 131
MR - Mauritania 131
GT - Guatemala 130
HR - Croazia 130
TJ - Tagikistan 130
CW - ???statistics.table.value.countryCode.CW??? 129
MK - Macedonia 128
UY - Uruguay 128
LA - Repubblica Popolare Democratica del Laos 127
LV - Lettonia 127
PT - Portogallo 127
BG - Bulgaria 126
TT - Trinidad e Tobago 125
GN - Guinea 124
MG - Madagascar 124
ZM - Zambia 124
HU - Ungheria 123
Totale 102.917
Salva come PNG Salva come JPEG
Città #
Singapore 5.645
Fairfield 5.239
San Jose 5.096
Ashburn 4.936
Woodbridge 3.173
Hong Kong 2.983
Chandler 2.678
Houston 2.626
Ann Arbor 2.442
Wilmington 1.876
Seattle 1.848
Cambridge 1.778
Ho Chi Minh City 1.454
Jacksonville 1.189
Hanoi 1.166
Boardman 1.048
Los Angeles 997
Santa Clara 988
Beijing 828
Princeton 828
Bytom 779
Lauterbourg 651
Helsinki 583
Medford 571
San Diego 536
Dong Ket 509
New York 507
Roxbury 429
Nanjing 383
Des Moines 358
Padova 325
Guangzhou 293
Da Nang 283
São Paulo 260
Munich 254
Chicago 249
Baghdad 215
Milan 214
Rome 208
Tashkent 208
Buffalo 203
Dublin 187
Tokyo 183
Haiphong 182
Dallas 169
Amman 167
Abidjan 165
Council Bluffs 159
Shenyang 157
Luanda 152
Panama City 151
Nairobi 150
Cotonou 146
Dakar 142
Orem 138
London 134
San José 133
Addis Ababa 131
Hefei 131
Nanchang 126
Baku 125
Managua 125
Bishkek 122
Conakry 122
Istanbul 120
Vienna 119
Lusaka 118
Sabadell 118
Frankfurt am Main 117
Ulan Bator 117
Dushanbe 115
Vientiane 114
Libreville 113
Nouakchott 113
Phnom Penh 113
Riga 112
Kampala 110
Hebei 109
Lahore 108
Turku 108
Kingston 107
Tianjin 107
Willemstad 107
Antananarivo 106
Riyadh 106
Praia 105
Brooklyn 104
Castries 104
Noumea 104
Shanghai 104
Bridgetown 103
Nassau 103
Tallinn 103
Atlanta 101
Bamako 101
Montevideo 101
Tirana 101
Changsha 100
Johannesburg 99
Ouagadougou 98
Totale 64.121
Salva come PNG Salva come JPEG
Nome #
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study 419
Fam20C-mediated phosphorylation of osteopontin is critical for its secretion but dispensable for its action as a cytokine in the activation of hepatic stellate cells in liver fibrogenesis 412
Frailty and sarcopenia in patients with cirrhosis awaiting liver transplantation: evidence from a single-centre, prospective cohort study 409
A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy 379
Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections 359
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection 353
Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure 344
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 341
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial 339
The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial 339
The animal naming test: An easy tool for the assessment of hepatic encephalopathy 332
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting 328
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease 325
Tocilizumab for severe COVID-19 pneumonia 320
Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes 315
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 315
Real-world experience with long-term albumin in patients with cirrhosis and ascites 313
Inhibition of Epoxyeicosatrienoic Acid Production in Rats With Cirrhosis Has Beneficial Effects on Portal Hypertension by Reducing Splanchnic Vasodilation 303
Positive cardiac inotropic effect of albumin infusion in rats with cirrhosis and ascites: Molecular mechanisms 302
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis 300
New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine? 299
Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis 298
Overt Hepatic Encephalopathy: More Than Meets the Eye 292
Abnormalities in the 24-hour Rhythm of Skin Temperature in Cirrhosis: Sleep-Wake and General Clinical Implications 291
Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19 289
Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis 287
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study 286
Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. 285
Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome 284
Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features 283
Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. 282
LAPAROSCOPIC ABLATION AND SALVAGE TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA 280
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment 278
Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy 278
Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence 276
THE USE OF OCTOGENARIAN DONORS FOR LIVER TRANSPLANT 276
Model for end-stage liver disease-sodium and survival benefit in liver transplantation. 275
Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. 274
The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability 273
Cost-effectiveness of Pre-Transplant Sofosbuvir for Preventing Recurrent HCV Infection after Liver Transplantation. 272
A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation:the first report on the application of VAC therapy 271
Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. 271
Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation 270
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 268
Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study 266
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 265
Changes in Accident & Emergency Visits and Return Visits in Relation to the Enforcement of Daylight Saving Time and Photoperiod 263
Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report 262
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide 262
New clinical and pathophysiological perspectives defining the trajectory of cirrhosis 261
Liver Fibrosis and Steatosis in Alstrom Syndrome: A Genetic Model for Metabolic Syndrome 260
The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial 259
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. 259
Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event 258
The influence of HE history, HE status and neuropsychological test type on learning ability in patients with cirrhosis 257
A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis 255
Covert hepatic encephalopathy: agreement and predictive validity of different indices 255
Arteroportal fistulas between the accessory right hepatic, gastroduodenal and superior mesenteric arteries and portal vein: a difficult technical problem to overcome in liver transplantation 254
Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation 254
Can the Multidimensional Prognostic Index (MPI) be a predictive instrument for mortality in older adult liver transplant candidates? 253
Acute Kidney Injury Network (AKIN) criteria in the detection of renal failure in patients with cirrhosis, ascites and a serum creatinine < 1.5 mg/dl 253
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure 251
Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy 251
Sequential versus "ab initio' combined diuretic treatment of moderate ascites in cirrhotic patients: Final results of a randomized controlled multicenter clinical study 249
Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation? 249
The liver: Another organ involved in Muir Torre syndrome? 249
Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation 247
The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study 246
ERP correlates of cognitive control and food-related processing in normal weight and severely obese candidates for bariatric surgery: Data gathered using a newly designed Simon task 246
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure 246
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. 245
A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy 244
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 244
miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals 242
First evidence that albumin can directly improve cardiac contractility in cirrhotic rats 242
Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases 242
Infections complicating cirrhosis 242
Twenty-five percent human albumin solution in clinical practice: indications, risks and monitoring protocols 241
Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis 240
Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be". 239
Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis 239
Endoscopic diode laser therapy for gastric hyperplastic polyps in cirrhotic patients 239
Acute liver rejection: Accuracy and predictive values of Doppler US measurements - Initial experience 238
Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus 237
Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. 237
Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine 236
Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites 236
Psychological predictors of poor weight loss following LSG: relevance of general psychopathology and impulsivity 236
Abnormalities in the 24-hour rhythm of skin temperature in cirrhosis: Sleep-wake and general clinical implications 235
Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. 235
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial 233
Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis 233
The survival benefit of liver transplantation in hepatocellular carcinoma patients 231
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis 231
Terlipressin given by continuous i.v. infusion versus i.v. boluses in the treatment of hepatorenal syndrome: A randomized controlled study. 231
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology 231
An Abnormal Gene Expression of the beta-Adrenergic System Contributes to the Pathogenesis of Cardiomyopathy in Cirrhotic Rats 230
Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the milan criteria 230
Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. 230
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma 230
Totale 27.314
Salva come PNG Salva come JPEG
Categoria #
all - tutte 306.537
article - articoli 243.324
book - libri 2.650
conference - conferenze 0
curatela - curatele 0
other - altro 764
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.105
Totale 558.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.834 0 1.028 652 433 355 374 403 622 366 202 588 1.811
2022/20235.594 1.269 499 187 583 948 778 20 316 628 36 273 57
2023/20242.650 149 405 274 227 160 227 176 102 114 94 384 338
2024/202513.917 34 1.084 704 543 1.707 380 625 962 1.331 562 2.368 3.617
2025/202654.743 1.898 4.674 7.856 8.107 4.845 2.254 7.463 4.577 6.142 3.208 2.125 1.594
2026/20272.705 2.264 441 0 0 0 0 0 0 0 0 0 0
Totale 109.628